Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells

[1]  C. Bailly,et al.  Drugs targeting mitochondrial functions to control tumor cell growth. , 2005, Biochemical pharmacology.

[2]  R. Blaheta,et al.  Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies , 2005, Medicinal research reviews.

[3]  Clara Nervi,et al.  Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. , 2005, Cancer research.

[4]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[5]  M. Michaelis,et al.  Valproic acid and interferon-α synergistically inhibit neuroblastoma cell growth in vitro and in vivo , 2004 .

[6]  M. Esteller,et al.  Histone deacetylase inhibitors: Understanding a new wave of anticancer agents , 2004, International journal of cancer.

[7]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[8]  F. Frediani.  Anticonvulsant drugs in primary headaches prophylaxis , 2004, Neurological Sciences.

[9]  S. Minucci,et al.  Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors , 2004, Apoptosis.

[10]  N. Brunello.  Mood stabilizers: protecting the mood...protecting the brain. , 2004, Journal of affective disorders.

[11]  R. Busse,et al.  Valproic acid inhibits angiogenesis in vitro and in vivo. , 2004, Molecular pharmacology.

[12]  J. Meinkoth,et al.  Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation , 2004, Cancer Research.

[13]  I. Zachary.  VEGF signalling: integration and multi-tasking in endothelial cell biology. , 2003, Biochemical Society transactions.

[14]  Frederick K Goodwin,et al.  Suicide risk in bipolar disorder during treatment with lithium and divalproex. , 2003, JAMA.

[15]  J. Trapani,et al.  A new quantitative assay for cytochrome c release in apoptotic cells , 2003, Cell Death and Differentiation.

[16]  Yili Yang,et al.  Regulation of apoptosis: the ubiquitous way , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  J. McCubrey,et al.  Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). , 2003, International journal of oncology.

[18]  O. Werz,et al.  Cell type‐dependent activation of 5‐lipoxygenase by arachidonic acid , 2003, Journal of leukocyte biology.

[19]  U. Förstermann,et al.  Inhibitors of Histone Deacetylation Downregulate the Expression of Endothelial Nitric Oxide Synthase and Compromise Endothelial Cell Function in Vasorelaxation and Angiogenesis , 2002, Circulation research.

[20]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[21]  O. Werz,et al.  Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. , 2002, Blood.

[22]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[23]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[24]  H. Manji,et al.  The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth* , 2001, The Journal of Biological Chemistry.

[25]  J. Gutkind,et al.  G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.

[26]  Wenbiao Liu,et al.  Endothelial cell survival and apoptosis in the tumor vasculature , 2000, Apoptosis.

[27]  V. Berezin,et al.  Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. , 1998, European journal of pharmacology.

[28]  V. Dixit,et al.  Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[29]  A. Karsan,et al.  Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. , 1997, The American journal of pathology.

[30]  R. Kavlock,et al.  Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture. , 1997, Teratology.

[31]  F. Ebbesen,et al.  Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. , 1993, Archives of disease in childhood.

[32]  F. Tamanoi,et al.  Identification of Ras farnesyltransferase inhibitors by microbial screening. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Nau,et al.  Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. , 1991, Pharmacology & toxicology.

[34]  S. Ohdo,et al.  Sodium valproate-induced cardiovascular abnormalities in the Jcl:ICR mouse fetus: peak sensitivity of gestational day and dose-dependent effect. , 1991, Teratology.

[35]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[36]  M. Michaelis,et al.  Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. , 2004, International journal of oncology.

[37]  L. Citrome.  Schizophrenia and valproate. , 2003, Psychopharmacology bulletin.

[38]  E. Perucca,et al.  Pharmacological and Therapeutic Properties of Valproate , 2002, CNS drugs.

[39]  H. Nau.  Valproic acid-induced neural tube defects. , 1994, Ciba Foundation symposium.